In what year will Loyal get FDA conditional approval for a daily dog-longevity pill?
Chance it happens
71%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
The FDA (CVM) grants conditional approval to a Loyal drug for canine lifespan extension. Resolution horizon: 2029-12-31. Source: FDA, Loyal.
Description
Loyal (legal name Cellular Longevity, Inc.) is a San Francisco biotech developing the first drugs designed specifically to extend healthy lifespan in dogs. The "daily pill" in this question is LOY-002: a beef-flavored chewable tablet given once a day to senior dogs. Instead of treating one disease, it targets age-related metabolic dysfunction — the gradual decline in how an aging body handles glucose and energy — which Loyal argues is an upstream driver of many age-associated diseases. The aim is more healthy years, not just treating illness after it appears. The STAY study is LOY-002's pivotal efficacy trial — the large, real-world study whose results are meant to prove the drug works. It is double-blinded and placebo-controlled (half the dogs get the drug, half get a placebo, and neither owners nor vets know which), runs up to four years across about 70 veterinary clinics, and enrolled more than 1,300 dogs aged 10 or older weighing at least 14 lb. Enrollment finished in July 2025, and Loyal calls it the largest clinical trial in the history of veterinary medicine. Details and eligibility: https://loyal.com/clinical-trials To reach market, LOY-002 must clear three technical sections of the FDA Center for Veterinary Medicine's conditional-approval pathway: Reasonable Expectation of Effectiveness (accepted February 2025), Target Animal Safety (accepted January 2026), and Chemistry, Manufacturing and Controls, or CMC (still outstanding, with review anticipated in 2027). Conditional approval is an accelerated route: it lets a drug be sold legally for up to five years while the full efficacy data — here, the STAY results — are still being collected, as long as safety and a reasonable expectation of effectiveness are already established. So in plain words, this market asks: in which calendar year will the FDA grant that conditional approval, letting Loyal sell the LOY-002 daily pill? Resolution horizon: 2029.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a Loyal company blog post announcing that the FDA accepted the Target Animal Safety section of LOY-002’s Expanded Conditional Approval application. It directly bears on the forecast because it shows concrete regulatory progress toward possible FDA conditional approval for a canine lifespan-extension drug before 2029-12-31.
This is Loyal's official website describing its dog-longevity drug program and prominently stating that LOY-002 has reached a key FDA milestone. It is directly relevant because it is a primary company source about regulatory progress toward an FDA-approved canine lifespan-extension drug.
This appears to be a LinkedIn post by Loyal CEO Celine Halioua announcing that LOY-002 earned FDA safety approval and that Loyal has completed 2 of 3 major sections of its conditional approval application. It is directly relevant because it indicates concrete regulatory progress toward potential FDA conditional approval of a daily dog-longevity pill.
This is an official Loyal page for dog owners that prominently states LOY-002 has reached a key FDA milestone. As a company statement about regulatory progress on a dog-longevity drug, it is relevant evidence for forecasting whether Loyal will obtain FDA conditional approval by 2029.
This is a company post stating that LOY-002's safety submission was accepted by the FDA and that Loyal had completed 2 of 3 major requirements for conditional approval for senior dog lifespan extension. It is directly relevant because it indicates progress toward the specific FDA conditional approval milestone in the prediction.
This is a 2026 Substack analysis post by a veterinarian discussing Loyal's LOY-002 dog-longevity program and its FDA regulatory progress. It bears on the prognosis because it reports that FDA accepted LOY-002's Reasonable Expectation of Effectiveness application in February 2025 and the Target Animal Safety submission in December 2025, indicating progress toward conditional approval.